|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FBXO18 |
Gene summary for FBXO18 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FBXO18 | Gene ID | 84893 |
| Gene name | F-box DNA helicase 1 | |
| Gene Alias | FBXO18 | |
| Cytomap | 10p15.1 | |
| Gene Type | protein-coding | GO ID | GO:0000018 | UniProtAcc | B3KV95 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84893 | FBXO18 | P1T-E | Human | Esophagus | ESCC | 4.94e-07 | 4.40e-01 | 0.0875 |
| 84893 | FBXO18 | P2T-E | Human | Esophagus | ESCC | 2.30e-14 | 2.25e-01 | 0.1177 |
| 84893 | FBXO18 | P4T-E | Human | Esophagus | ESCC | 2.73e-21 | 3.72e-01 | 0.1323 |
| 84893 | FBXO18 | P5T-E | Human | Esophagus | ESCC | 2.64e-11 | 1.04e-01 | 0.1327 |
| 84893 | FBXO18 | P8T-E | Human | Esophagus | ESCC | 7.05e-08 | 1.86e-01 | 0.0889 |
| 84893 | FBXO18 | P9T-E | Human | Esophagus | ESCC | 5.66e-10 | 9.18e-02 | 0.1131 |
| 84893 | FBXO18 | P10T-E | Human | Esophagus | ESCC | 2.36e-10 | 1.21e-01 | 0.116 |
| 84893 | FBXO18 | P11T-E | Human | Esophagus | ESCC | 1.10e-10 | 1.81e-01 | 0.1426 |
| 84893 | FBXO18 | P12T-E | Human | Esophagus | ESCC | 2.88e-23 | 3.53e-01 | 0.1122 |
| 84893 | FBXO18 | P15T-E | Human | Esophagus | ESCC | 3.04e-19 | 2.24e-01 | 0.1149 |
| 84893 | FBXO18 | P16T-E | Human | Esophagus | ESCC | 2.75e-15 | 1.68e-01 | 0.1153 |
| 84893 | FBXO18 | P17T-E | Human | Esophagus | ESCC | 4.44e-03 | 1.36e-01 | 0.1278 |
| 84893 | FBXO18 | P19T-E | Human | Esophagus | ESCC | 7.01e-08 | 3.35e-01 | 0.1662 |
| 84893 | FBXO18 | P20T-E | Human | Esophagus | ESCC | 1.21e-13 | 8.84e-02 | 0.1124 |
| 84893 | FBXO18 | P21T-E | Human | Esophagus | ESCC | 6.19e-20 | 3.40e-01 | 0.1617 |
| 84893 | FBXO18 | P22T-E | Human | Esophagus | ESCC | 2.01e-12 | 6.56e-02 | 0.1236 |
| 84893 | FBXO18 | P23T-E | Human | Esophagus | ESCC | 2.23e-15 | 2.13e-01 | 0.108 |
| 84893 | FBXO18 | P24T-E | Human | Esophagus | ESCC | 8.33e-13 | 2.38e-01 | 0.1287 |
| 84893 | FBXO18 | P26T-E | Human | Esophagus | ESCC | 7.22e-15 | 1.63e-01 | 0.1276 |
| 84893 | FBXO18 | P27T-E | Human | Esophagus | ESCC | 1.47e-17 | 2.47e-01 | 0.1055 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FBXO18 | SNV | Missense_Mutation | rs770104196 | c.2623N>G | p.Tyr875Asp | p.Y875D | Q8NFZ0 | protein_coding | deleterious(0.01) | probably_damaging(0.979) | TCGA-A2-A0T2-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | xeloda | PD |
| FBXO18 | SNV | Missense_Mutation | rs774015746 | c.1549N>A | p.Gly517Ser | p.G517S | Q8NFZ0 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A2-A0YD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
| FBXO18 | SNV | Missense_Mutation | rs770104196 | c.2623T>G | p.Tyr875Asp | p.Y875D | Q8NFZ0 | protein_coding | deleterious(0.01) | probably_damaging(0.979) | TCGA-A7-A26G-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
| FBXO18 | SNV | Missense_Mutation | c.1636G>A | p.Ala546Thr | p.A546T | Q8NFZ0 | protein_coding | deleterious(0.01) | possibly_damaging(0.457) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| FBXO18 | SNV | Missense_Mutation | rs770104196 | c.2623N>G | p.Tyr875Asp | p.Y875D | Q8NFZ0 | protein_coding | deleterious(0.01) | probably_damaging(0.979) | TCGA-AR-A255-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | trastuzumab | SD |
| FBXO18 | SNV | Missense_Mutation | rs770104196 | c.2623N>G | p.Tyr875Asp | p.Y875D | Q8NFZ0 | protein_coding | deleterious(0.01) | probably_damaging(0.979) | TCGA-BH-A1F5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| FBXO18 | SNV | Missense_Mutation | rs770104196 | c.2623N>G | p.Tyr875Asp | p.Y875D | Q8NFZ0 | protein_coding | deleterious(0.01) | probably_damaging(0.979) | TCGA-BH-A1FH-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| FBXO18 | SNV | Missense_Mutation | rs770104196 | c.2623T>G | p.Tyr875Asp | p.Y875D | Q8NFZ0 | protein_coding | deleterious(0.01) | probably_damaging(0.979) | TCGA-BH-A1FR-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| FBXO18 | SNV | Missense_Mutation | c.2943N>G | p.Ile981Met | p.I981M | Q8NFZ0 | protein_coding | deleterious(0.01) | probably_damaging(0.954) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| FBXO18 | SNV | Missense_Mutation | c.2580C>G | p.Ile860Met | p.I860M | Q8NFZ0 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-E2-A14V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |